Multi-kinase inhibitor: BCR-ABL, SRC family, EPHA2, PDGFR, KIT. In oncology, treats Ph+ ALL + CML (imatinib-resistant). Recent research interest as a senolytic — paired with quercetin, selectively clears senescent cells in preclinical + early human (IPF, diabetic kidney disease) trials.
Half-Life & Elimination Curve (PO: 4h)
Plasma (PO)t½ Decay (4h)
0×t½0h100%(6.22 µg/L)
1×t½4h50%(3.11 µg/L)
2×t½8h25%(1.56 µg/L)
3×t½12h12.5%(0.778 µg/L)
4×t½16h6.3%(0.389 µg/L)
5×t½20h3.1%(0.195 µg/L)
Elimination t½4h (PO)
Rate Constant (ke)0.173 h⁻¹
Time to Peak (Tmax)1.1h
Est. Peak (Cmax)6.22 µg/L
Clearance (CL)364 L/h
97% Washout (5×t½)20h
Dosing Guidelines
Oral (PO): Typical 113 mg (Range: 100–140 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 14% · Volume of Distribution (Vd): 2100 L · Absorption (ka): 2.65 h⁻¹ (t½ka ≈ 16m) [PMID 32112275]